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MicroRNAs (miRNAs) exhibit tumor-speciﬁc expression signatures and play crucial roles in tumor-
igenesis by targeting oncogenes. Here, through analyzing the miRNA-array proﬁles of human glio-
blastoma tissues and the adjacent normal brain tissues, we found miR-483–5p was signiﬁcantly
down-regulated in gliomas, which was conﬁrmed in both human glioma specimens and cell lines.
The overexpression of miR-483–5p suppressed glioma cell proliferation and induced a G0/G1 arrest.
In contrast, miR-483–5p inhibition promoted cell proliferation. Furthermore, by a dual-luciferase
reporter assay and expression analysis, we identiﬁed extracellular signal-regulated kinase 1
(ERK1) as a direct target of miR-483–5p. ERK1 knockdown can block cell proliferation induced by
miR-483–5p inhibition. Thus, our ﬁndings provide the ﬁrst evidence that miR-483–5p can serve as
a tumor suppressor in gliomas.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction various human malignancies. Additionally, deregulated miRNAsGliomas are the most common primary malignant brain tumors
in adults and display high mortality due to aggressive, neurologi-
cally destructive and recurrent characteristic features. Although
remarkable progress has been made on treatments to improve
patient outcomes, the median survival time of a patient with glio-
blastoma, the most malignant form of gliomas, is less than two
years [1]. This poor prognosis is mostly attributed to our incom-
plete knowledge of the molecular mechanisms by which glioma-
genesis is initiated and promoted, and this situation greatly
hampers the development of effective therapies and satisfactory
responses to available treatments. Recent advances in epigenetics
have revealed a class of microRNAs (miRNAs) that are functionally
important in the development of tumors. Thus, it will be helpful to
discover determinant miRNAs in gliomagenesis and mechanisms
involved in gliomagenesis to overcome this formidable neoplasm.
miRNAs are small, endogenous, non-coding RNA molecules that
negatively regulate gene expression through complementarity to
the 30 untranslated region (30-UTR) of mRNAs [2]. Targeting multi-
ple genes, miRNAs show pleiotropic and pivotal effects on a variety
of physiological and pathological cellular processes. Aberrant
miRNA expression is often associated with the development ofchemical Societies. Published by E
ular regulated kinase1; UTR,
Y. Deng).
g), yanchundeng@yahoo.comexhibit oncogenic or tumor suppressor properties [3]. However,
only a small fraction of miRNAs have been experimentally exam-
ined, among which miR-21 has been well-studied in gliomas.
miR-21, which is up-regulated in many solid tumors, inhibits
caspase-3 dependent apoptosis in glioma cells and promotes tu-
mor formation in vivo [4]. MiR-21 also facilitates cell invasion by
directly targeting metalloprotease inhibitors TIMP3 and RECK [5].
Moreover, dysregulation of miR-21 expression is associated with
chemotherapy resistance in tumor cells [6]. In addition to up-
regulated miRNAs in gliomas, like miR-21, the expression of a
group of miRNAs were also found to be down-regulated. However,
the functions of these miRNAs are relatively less studied in gliomas
at present.
In this study, we ﬁrst identiﬁed a down-regulated miRNA,
miR-483–5p, in human gliomas in comparison with normal brain
tissues, and found that miR-483–5p can suppress glioma cell
proliferation via directly targeting extracellular signal-regulated
kinase 1 (ERK1).
2. Materials and methods
2.1. Human tissue samples and cell culture
All human glioma tissue samples and adjacent normal brain
tissues were obtained from the Department of Neurosurgery at
Xijing Hospital, Xi’an, China. The fresh samples were resected at
the ﬁrst surgery before any treatment and were immediatelylsevier B.V. All rights reserved.
Fig. 1. miR-483–5p was down-regulated in human primary gliomas and cell lines
compared to normal brain tissues. Quantitative RT-PCR analysis of miR-483–5p (A)
and miR-7 (B) in nine glioma tissues (T1–T3 grade II, T4–T6 grade III, T7–T9 grade
IV), three glioma cell lines and three normal brain tissues. Normal brain tissues:
N1–N3. Cell lines: U87, U251, SHG44. Relative expression of miRNAs was
normalized to that of U6 snRNA. ⁄⁄P < 0.01, compared with normal brain tissues.
Fig. 2. Ectopic expression of miR-483–5p inhibited cell proliferation. Growth
curves of U87 cells (A) and U251 cells (B) stably transfected with miR-483–5p, miR-
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were classiﬁed according to the World Health Organization criteria
that were published in 2000. This study was approved by the Insti-
tutional Review Board of Xijing Hospital. Human embryonic kidney
cells (HEK293T) and human glioma cell lines (U87, U251 and
SHG44) were maintained in DMEM supplemented with 10% FBS
at 37 C in a humidiﬁed incubator containing 5% CO2.338–3p or negative control vectors. The number of viral cells was measured
according to the absorbance value at 570 nm with a reference wavelength o
630 nm. The values represent the mean ± S.D. for six wells. (C) MTT assay of U251
cells 48 h after transient transfection with anti-miR-483–5p or with the negative
control. ⁄P < 0.05, ⁄⁄P < 0.01, compared with control.2.2. miRNA microarray
miRNA expression proﬁling was performed using total RNAwith
the human/rodent Exiqon (208101-A)miRNAMicroarray by Lifegen
Co. (Shaanxi, China) and analyzed using the Signiﬁcance Analysis of
Microarrays (SAM) version 3.0 as previously described [7].
2.3. Quantitative RT-PCR
The relative expression of miRNAs were determined using the
method described previously [8]. The data were analyzed using
the 2DDCT method for relative quantitation [9]; human U6 snRNA
served as an endogenous control.
2.4. Constructs and cell transfection
A 548-bp genomic sequence spanning miRNA-483–5p was
ampliﬁed using primers miR-483–5p-F/R (SupplementaryfTable S1) and then cloned into the pLenti6.3/V5-DEST Gateway Vec-
tor (Invitrogen, USA); lentiviruses were packaged in HEK293T cells
according to the manufacturer’s instructions. A 593-bp sequence
containingmiR-338–3pwas similarly introduced into empty lentiv-
iruses. Glioma cells were infected with lentiviruses and selected
using blasticidin (Invitrogen) at the appropriate concentrations for
four weeks. The cells stably transfected with pLenti6.3/V5-cherry
were used as a control. The ERK1 30-UTR fragment (position 1529–
1849; GenBank ID: NM 002746.2) was cloned downstream of the
ﬁreﬂy luciferase gene using the XbaI and EcoRI site in the recon-
structed pGL3-control plasmid (Promega, USA). For itsmutagenesis,
the sequence complementary to the seed region of miR-483–5p in
its 30-UTR (CCCGTCT) was replaced by CCGCAGT. For ERK1-siRNA
constructs, three pairs of chemically synthesized oligonucleotides
Fig. 4. ERK1 is a target of miR-483–5p. (A) The bioinformatic schematic of ERK1
regulated by miR-483–5p in the ERK1 30-UTR. The mutated site of ERK1 30-UTR is
indicated in underlined italics. (B) Luciferase assay. HEK293T cells were transiently
co-transfected with luciferase reporter constructs, miR-483–5p or control miRNA
expressing vector. The relative luciferase activities were normalized against the
Renilla luciferase activities. The data are expressed as percentages of the relative
luciferase activities of pGL3-control. ⁄⁄P < 0.01, compared with the empty plasmid.
Fig. 3. Overexpression ofmiR-483–5p induced an accumulation of U87 (A) andU251
(B) cells in the G1 phase with corresponding decreases in the S phase and the G2/M
phase compared with the negative control cells. ⁄P < 0.05, ⁄⁄P < 0.01, compared with
control.
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PER.neo + gfp vector (OligoEngine Inc., USA) as described previously
[10]. miR-483–5p inhibitor (Anti-miR-483–5p) and NC Inhibitors
were purchased from Shanghai GenePharma Co. (Shanghai, China).
Cells were transfectedwith plasmids or oligonucleotides using lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
instruction. After 48 h of incubation, total RNA and cellular protein
were extracted and subjected to quantitative RT-PCR and western
blot analyses, respectively.
2.5. Luciferase assay
HEK293T cells were plated in a 48-well plate 24 h before trans-
fection. The next day, the cells were co-transfected with the repor-
ter constructs containing 400 ng wild-type or mutant ERK1–30UTR
reporter plasmids, miR-483–5p expressing vectors and pRL-TK.
Then, the luciferase activities were determined as previously de-
scribed using GloMax 20/20 Luminometer system (Promega) [11].
2.6. Statistical analysis
The data were presented as the mean ± S.D. The differences
between groups were calculated using a Student’s t-test or one-
way ANOVA. P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. The expression of miR-483–5p is decreased in glioma tissues and
cell lines
To identify miRNAs that are potentially involved in gliomagene-
sis, we extracted total RNA from three pairs of human glioblastomaand the adjacent normal brain tissue and performed a microarray
analysis. We limited our study to miRNAs whose levels changed at
least 2-fold in glioma tissue relative to the normal brain tissue con-
trol and obtained 91 miRNAs, some of which had been identiﬁed in
previous reports (Table S3). Among thesemiRNAs,miR-483–5pwas
down-regulated by almost 100-fold. Because its role in human
malignancies remains unclear, we chose miR-483–5p for further
study.
First, we examined the expression level of miR-483–5p in a
cohort of glioma tissues and cell lines by quantitative RT-PCR to
conﬁrm our microarray results. MiR-7, expressing at a low level
in glioblastoma [12], was used as a positive control for miRNA
speciﬁcity. As shown in Fig. 1A, the expression of miR-483–5p
was signiﬁcantly reduced in nine glioma tissues and three cell lines
by 4- to 335-fold compared to the mean expression level of miR-
483–5p in three normal brain tissues. However, no correlation
was observed between the miR-483–5p expression level and the
glioma pathological grade (data not shown). Consistent with previ-
ous reports, miR-7 exhibited a down-regulated expression pattern
with 11- to 87-fold reduction in all examined glioma tissues and
cell lines (Fig. 1B). These results indicate that miR-483–5p expres-
sion is signiﬁcantly decreased in human glioma specimens and cell
lines.
3.2. MiR-483–5p inhibits glioma cell proliferation by inducing G0/G1
arrest
To examine the role of miR-483–5p in glioma cell proliferation,
we transfected U251 or U87 cells with miR-483–5p and anti-miR-
483–5p for overexpression and knockdown assays, respectively.
Fig. 5. The effect of miR-483–5p on ERK1 expression. U251 were transfected with anti-miR NC or anti-miR-483–5p, whereas U87 cells were transfected with miR control or
miR-483–5p, respectively. After 48 h, total cells were collected for western blotting (A/B) and qRT-PCR (C/D) to detect the expression of ERK1. The results were quantiﬁed and
presented with the data from three independent experiments. Tub: b-tubulin. Anti-miR: anti-miR-483–5p. ⁄P < 0.05, ⁄⁄P < 0.01, compared with control.
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tion (Fig. S1). Stably transfected U87 and U251 cells that overex-
pressed miR-483–5p were subjected to an MTT assay at 24, 48,
72 and 96 h. Our data showed that both cell lines exhibited a sig-
niﬁcantly decreased proliferation rate compared to the control at
72 h and 96 h. Additionally, transfection of another downregulated
miRNA identiﬁed from our microarray assay, miR-338–3p, had no
such effect (Fig. 2A/B). By contrast, miR-483–5p knockdown signif-
icantly promoted the proliferation of U251 cells at 48 h (Fig. 2C).
These data indicate that miR-483–5p suppresses the proliferation
of human glioma cells and may serve as a potential glioma
suppressor.
We investigated the mechanism underlying the growth inhibi-
tion by miR-483–5p in glioma cells by observing the changes in
the cell cycle phase distribution after miR-483–5p transfection. In
contrast to the control, we detected a signiﬁcant increase in the
percentage of U87 (about 10%) and U251 cells (about 16%) in the
G1/G0 phase of the cell cycle (Fig. 3). These changes were accompa-
nied by a decrease of cell populations at both the S phase and theG2/
M phase after miR-483–5p-transfection. Thus, these results suggest
that miR-483–5p inhibits glioma cell proliferation at least through
arresting the cells in the G0/G1 phase.
3.3. ERK1 is a direct target of miR-483–5p
We next explored the possible targets of miR-483–5p. Interest-
ingly, taking advantage of recently released database (http://
www.microrna.org/), we found that the tumor-proliferation-associated ERK1carriedoneputativemiR-483–5pbinding site in the
30-UTRand that their alignmenthas thehighestmirSVR score among
predicted ERK1-regulating miRNAs (Fig. 4A). To determine whether
miR-483–5p could target the ERK1 gene, dual luciferase assayswere
performed in HEK293T cells using constructs containing this puta-
tive binding site downstream of the reporter gene. As shown in
Fig. 4B, miR-483–5p reduced the ERK1 30-UTR luciferase activity
by 40% when compared to the control. Moreover, the repression
of luciferase activity was signiﬁcantly attenuated when pGL3-
ERK1–30-UTR was replaced by pGL3-ERK1–30-UTRmut (Fig. 4B).
Subsequently, we assessed whether endogenous ERK1 would be
down-regulated bymiR-483–5p. To address this issue, western blot
analysis and quantitative RT-PCR were performed to evaluate ERK1
expression after miR-483–5p or anti-miR-483–5p transfection in
glioma cells. The data showed that anti-miR-483–5p induced the
expression of ERK1 protein and mRNA (Fig. 5A and C), whereas
miR-483–5p overexpression signiﬁcantly reduced the expression
levels of ERK1 protein and mRNA (Fig. 5B and D). Note that ERK1
protein level in U251 cells was lower than that in U87 cells. This
can be explained by a higher expression level of miR-483–5p in
U251 than that in U87 cells (Fig. 1A and Supplementary Fig. S2).
Taken together, these results demonstrate that ERK1 is directly
regulated by miR-483–5p at the post-transcriptional level.
3.4. MiR-483–5p inhibits glioma cell proliferation by targeting ERK1
To investigate whether the growth suppression induced by
miR-483–5p overexpression in glioma cells was due to the
Fig. 6. ERK1 mediation of miR-483–5p’s effects on glioma cell proliferation. (A) The
cell growth assay. U251 cells were grown and transiently transfected with
pSUPER.neo + gfp vector, ERK1 siRNA expressing vector, anti-miR-483–5p, or
ERK1 siRNA expressing vector plus anti-miR-483–5p. The cells were subjected to
MTT assay for cell proliferation analysis after 24 h and 48 h. (B) The western blot
assay of above cells 48 h after transfection. ⁄P < 0.05, ⁄⁄P < 0.01.
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miR-483–5p into U251 cells. Our results showed that transfection
of anti-miR-483–5p promoted glioma cell proliferation and upreg-
ulation of ERK1 expression, whereas transfection of ERK1 siRNA
decreased the number of glioma cells and the expression level of
ERK1. However, after co-transfection, the cell number and ERK1 le-
vel induced by anti-miR-483–5p were reversed (Fig. 6). These re-
sults suggest that miR-483–5p inhibits glioma cell proliferation
at least through suppressing ERK1 expression.
4. Discussion
Since miRNAs were identiﬁed almost a decade ago as a large
group of regulator genes, numerous researchers have sought to
illuminate the correlations between the aberrant expression levels
of speciﬁc miRNAs and the phenotypic changes of tumors. How-
ever, to completely understand the functional roles of miRNAs,
there needs to be a deeper exploration into the miRNA-mRNA
interaction network.In this study, we identiﬁed miR-483–5p as a novel therapeutic
candidate target in gliomas. Using a method that combined miR-
NA-array and qRT-PCR, we found that miR-483–5p expression
was down-regulated in all tested glioma tissues and glioma cells.
A previous miRNA array study indicated that miR-483 was
down-regulated in glioblastomas [13]. Consistent with their result,
this work provides new evidence of aberrant miR-483–5p expres-
sion in human glioma. These data suggest that the dysregulation of
miR-483–5p might be a common occurrence in gliomagenesis. In
contrast, several studies reported the opposite expression pattern
of miR-483–5p in adrenocortical cancer and pheochromocytomas
[14–16]. Considering that the gene expression proﬁle is tumor spe-
ciﬁc and that the inﬂuence of miRNAs alterations might strongly
depend on tumor context [17,18], these are not surprising results.
We did not detect any relationship between the pathological grade
of gliomas and the expression of miR-483–5p while a larger num-
ber of glioma specimens should be included to conﬁrm this result.
The miR-483–5p gene is located on genomic chromosome at
11p 15.5 in the second intron of IGF2 and produces two mature
forms (miR-483–5p, miR-483–3p). The functions of miR-483–5p
have been sparsely studied to date and its relevance to carcinogen-
esis remains unclear. Here we analyzed the proliferation rate of
glioma cells transfected with miR-483–5p or anti-miR-483–5p to
identify its anti-tumor property. Our results showed that the pro-
liferation capacity was repressed after restoration of miR-483–5p
expression in glioma cells, whereas the down-regulation of
miR-483–5p promoted glioma cell proliferation, indicating that
miR-483–5p might be a potential growth suppressor for gliomas.
Furthermore, we found that miR-483–5p exerts this growth sup-
pression through the inhibition of cell cycle progression from the
G0/G1 phase to the S phase.
It is well known that miRNAs can regulate the gene expression
of multiple targets to perform pleiotropic functions [19]. Herein,
through miRanda database we found several important candidate
targets, among which ERK1 is a direct target of the miR-483–5p
in the control of glioma cell proliferation. The ERK signaling path-
way is a central regulator in the control of cell proliferation and cell
differentiation [20,21]. Constitutive ERK activation has been shown
to be involved in the pathogenesis of many human malignancies
including gliomas [22]. In present study, using a luciferase reporter
system and expression assay, we conﬁrmed that ERK1 is negatively
regulated by miR-483–5p. A recent study in ischemic heart disease
suggested an additional role of miR-483–5p in angiogenesis inhibi-
tion mediated by its target SRF [23], suggesting that by controlling
different processes, miR-483–5p might inhibit tumorigenesis
through various functions. Addtionally, Although ERK2 is the struc-
turally related isoform of ERK1 and also contributes to cell prolif-
eration [24,25], we observed no signiﬁcant change in ERK2
expression after miR-483–5p manipulation.
In summary, our ﬁndings demonstrate that miR-483–5p inhib-
its the proliferation of glioma cells via directly regulating the
expression of ERK1, implying that miR-483–5p can serve as a po-
tential target in the treatment of gliomas.
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